Fasting blood glucose to lymphocyte ratio predicting the long-term cardiac mortality in unstable angina pectoris patients

Background: This retrospective study aims to explore the predictive value of the fasting blood glucose to lymphocyte count ratio (GLR) for coronary artery lesion severity and long-term cardiac mortality in patients with unstable angina pectoris (UAP), which has not been previously reported. Methods: 4110 patients with UAP were included in the study. The patients were classified into two groups based on their GLR values and were followed for an average of 36 months. Outcomes, including cardiac mortality, all-cause mortality, and rehospitalization rate, were analyzed, and the predictive value of GLR for long-term cardiac mortality was determined. Results: Among all patients, 865 (21.0%) were re-hospitalized and 103 (2.5%) died, including 39 cardiac deaths (0.9%). The high GLR group had a greater SYNTAX score compared to the low GLR group (p < 0.001). The cardiac mortality (p = 0.006) and rehospitalization (p = 0.004) rates were higher in the high GLR group. Kaplan-Meier curve indicated higher cardiac mortality when GLR was ≥3.38 (p = 0.005). Receiver operating characteristic (ROC) analysis revealed that a GLR of 2.9861 was an effective cutoff value for predicting cardiac mortality (p = 0.001). Multivariate Cox regression analysis showed that serum creatinine (p = 0.003), GLR (p = 0.029), and SYNTAX score (p < 0.001) were independent predictors of cardiac mortality. Conclusions: GLR was significantly correlated with coronary artery lesion severity and can be used as an independent predictor of cardiac mortality in patients with UAP.

Unstable angina pectoris (UAP); Fasting blood glucose to lymphocyte ratio (GLR); SYNTAX score; Cardiac mortality

[1] Fladseth K, Wilsgaard T, Lindekleiv H, Kristensen A, Mannsverk J, Løchen ML, et al. Outcomes after coronary angiography for unstable angina compared to stable angina, myocardial infarction and an asymptomatic general population. International Journal of Cardiology. Heart & Vasculature. 2022; 42: 101099.

[2] Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2021; 42: 1289–1367.

[3] Keykhaei M, Ashraf H, Rashedi S, Farrokhpour H, Heidari B, Zokaei S, et al. Differences in the 2020 ESC versus 2015 ESC and 2014 ACC/AHA guidelines on the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Current Atherosclerosis Reports. 2021; 23: 77.

[4] Piątek Ł, Janion-Sadowska A, Piątek K, Zandecki Ł, Zabojszcz M, Siudak Z, et al. Long-term clinical outcomes in patients with unstable angina undergoing percutaneous coronary interventions in a contemporary registry data from Poland. Coronary Artery Disease. 2020; 31: 215–221.

[5] Hammami R, Jdidi J, Mroua F, Kallel R, Hentati M, Abid L, et al. Accuracy of the TIMI and GRACE scores in predicting coronary disease in patients with non-ST-elevation acute coronary syndrome. Revista Portuguesa De Cardiologia. 2018; 37: 41–49.

[6] Çınar T, Şaylık F, Akbulut T, Korkmaz Y, Çiçek V, Asal S, et al. Evaluation of intermountain risk score for short- and long-term mortality in ST elevation myocardial infarction patients. Angiology. 2023; 74: 357–364.

[7] Oner E, Kahraman S, Agus HZ, Guner A, Dogan AC, Yildiz MM, et al. Naples score is associated with SYNTAX Score in patients with ST-segment elevation myocardial infarction. Coronary Artery Disease. 2023; 34: 504–509.

[8] Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, González-Garrido A, Villarreal-Molina T, Jacobo-Albavera L, et al. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. International Journal of Molecular Sciences. 2021; 22: 3850.

[9] Libby P, Pasterkamp G, Crea F, Jang I. Reassessing the mechanisms of acute coronary syndromes. Circulation Research. 2019; 124: 150–160.

[10] Xia J, Yin C. Glucose variability and coronary artery disease. Heart, Lung and Circulation. 2019; 28: 553–559.

[11] Feng W, Li Z, Guo W, Fan X, Zhou F, Zhang K, et al. Association between fasting glucose variability in young adulthood and the progression of coronary artery calcification in middle age. Diabetes Care. 2020; 43: 2574–2580.

[12] Sotomi Y, Collet C, Cavalcante R, Morel M, Suwannasom P, Farooq V, et al. Tools and techniques-clinical: SYNTAX score II calculator. EuroIntervention. 2016; 12: 120–123.

[13] Yılmaz A, Şimşek M, Hannarici Z, Büyükbayram ME, Bilici M, Tekin SB. The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib. Future Oncology. 2021; 17: 4545–4559.

[14] Zhang Y, Xu Y, Wang D, Kuang T, Wu W, Xu X, et al. Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer. International Journal of Clinical Oncology. 2021; 26: 135–144.

[15] Chen Y, Tang S, Wang Y. Prognostic value of glucose-to-lymphocyte ratio in critically ill patients with acute pancreatitis. International Journal of General Medicine. 2021; 14: 5449–5460.

[16] Navarro J, Kang I, Hwang HK, Yoon DS, Lee WJ, Kang CM. Glucose to lymphocyte ratio as a prognostic marker in patients with resected pT2 gallbladder cancer. Journal of Surgical Research. 2019; 240: 17–29.

[17] Hu T, Liu X, Liu Y. Usefulness of glucose to lymphocyte ratio to predict in-hospital mortality in patients with AECOPD admitted to the intensive care unit. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2022; 19: 158–165.

[18] Zhang Y, Zhang S. Prognostic value of glucose-to-lymphocyte ratio in critically ill patients with acute respiratory distress syndrome: a retrospective cohort study. Journal of Clinical Laboratory Analysis. 2022; 36: e24397.

[19] Yang M, Zhang Q, Ge YZ, Tang M, Hu CL, Wang ZW, et al. Prognostic roles of glucose to lymphocyte ratio and modified glasgow prognosis score in patients with non-small cell lung cancer. Frontiers in Nutrition. 2022; 9: 871301.

[20] Yang J, Zhou YJ, Zhang TY, Lin X, Ma X, Wang Z, et al. Fasting blood glucose and HBA1c correlate with severity of coronary artery disease in elective PCI patients with HbA1c 5.7% to 6.4. Angiology. 2020; 71: 167–174.

[21] Chen C, Chen YQ, Xiao JX, Zhang Y, Yang Z, Yang P, et al. Association of impaired fasting blood glucose with triple coronary artery stenosis and myocardial infarction among patients with coronary artery stenosis. Frontiers in Cell and Developmental Biology. 2022; 10: 820124.

[22] Naito R, Miyauchi K. Coronary artery disease and type 2 diabetes mellitus. International Heart Journal. 2017; 58: 475–480.

[23] Yamamoto H, Shinke T, Otake H, Kawamori H, Toba T, Kuroda M, et al. Impact of daily glucose fluctuations on cardiovascular outcomes after percutaneous coronary intervention for patients with stable coronary artery disease undergoing lipid-lowering therapy. Journal of Diabetes Investigation. 2021; 12: 1015–1024.

[24] Janjusevic M, Fluca AL, Gagno G, Pierri A, Padoan L, Sorrentino A, et al. Old and novel therapeutic approaches in the management of hyperglycemia, an important risk factor for atherosclerosis. International Journal of Molecular Sciences. 2022; 23: 2336.

[25] Alexander Y, Osto E, Schmidt-Trucksäss A, Shechter M, Trifunovic D, Duncker DJ, et al. Endothelial function in cardiovascular medicine: a consensus paper of the European society of cardiology working groups on atherosclerosis and vascular biology, aorta and peripheral vascular diseases, coronary pathophysiology and microcirculation, and thrombosis. Cardiovascular Research. 2021; 117: 29–42.

[26] Li S, Chen H, Zhou L, Cui H, Liang S, Li H. Neutrophil-to-lymphocyte ratio predicts coronary artery lesion severity and long-term cardiovascular mortality in patients with unstable angina pectoris. Acta Cardiologica. 2022; 77: 708–715.

[27] Saito Y, Tanaka A, Node K, Kobayashi Y. Uric acid and cardiovascular disease: a clinical review. Journal of Cardiology. 2021; 78: 51–57.

[28] Peter Libby. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovascular Research. 2021; 117: 2525–2536.

[29] Leistner DM, Kränkel N, Meteva D, Abdelwahed YS, Seppelt C, Stähli BE, et al. Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translational OPTICO-ACS study. European Heart Journal. 2020; 41: 3549–3560.

[30] Liu J, Hu X. Association between glucose-to-lymphocyte ratio and in-hospital mortality in acute myocardial infarction patients. PLOS ONE. 2023; 18: e0295602.

[31] Batra G, Ghukasyan Lakic T, Lindbäck J, Held C, White HD, Stewart RAH, et al. Interleukin 6 and cardiovascular outcomes in patients with chronic kidney disease and chronic coronary syndrome. JAMA Cardiology. 2021; 6: 1440–1445.

[32] Forrest IS, Petrazzini BO, Duffy Á, Park JK, Marquez-Luna C, Jordan DM, et al. Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts. The Lancet. 2023; 401: 215–225.

[33] Kayvanpour E, Gi W, Sedaghat-Hamedani F, Lehmann DH, Frese KS, Haas J, et al. MicroRNA neural networks improve diagnosis of acute coronary syndrome (ACS). Journal of Molecular and Cellular Cardiology. 2021; 151: 155–162.